Arvinas Secures $35M Upfront Payment as VEPPANU Licensing Deal with Rigel Becomes Effective
ARVN sits 23% above its 52-week low of $6.055.
Summary
Arvinas announced its VEPPANU licensing deal with Rigel Pharmaceuticals is now effective, bringing in $35 million upfront and securing future milestone payments and royalties.
Key Events · M&A and Partnerships · ARVN
-
Licensing Agreement Finalized
The global licensing agreement with Rigel Pharmaceuticals for VEPPANU is now effective following Hart-Scott-Rodino antitrust clearance.
-
Immediate Cash Infusion
Arvinas received $35.0 million as its share of the $70.0 million upfront payment from Rigel.
-
Additional Near-Term Payment
An additional $7.5 million is expected upon successful completion of development and manufacturing transition activities.
-
Future Milestones and Royalties
The company is eligible for up to $160.0 million in future development, regulatory, and commercial milestone payments, plus tiered royalties on worldwide net sales.
Analysis · ARVN · Life Sciences
This filing confirms the finalization of the global licensing agreement for VEPPANU with Rigel Pharmaceuticals, following HSR antitrust clearance. Arvinas immediately receives $35 million as its share of the upfront payment, with an additional $7.5 million expected upon completion of transition activities. This significant cash infusion, totaling $42.5 million in the near term, substantially strengthens the company's financial position and provides capital for ongoing operations and pipeline development. The deal also includes potential future milestone payments up to $160 million and tiered royalties, establishing a long-term revenue stream for its FDA-approved drug.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 40.6% of the 409 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ARVN was trading at $7.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $478.7M. The 52-week trading range was $6.06 to $14.51. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.